This open non-randomized controlled single center study investigates to what extent the removal of circulating Neutrophil Extracellular Traps (NETs) from blood by NucleoCapture device has a positive effect on the treatment of patients with sepsis and sepsis-associated AKI (SA-AKI).
Age range
18 Years – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Incidence of acute kidney injury (AKI)
Timeframe: from [start of treatment] through 28 days after
Severity of acute kidney injury (AKI)
Timeframe: from [start of treatment] through 28 days after
Rate of AKI transition to the more severe stage (for patients with AKI at baseline).
Timeframe: from [start of treatment] through 28 days after
Serum creatinine change over time
Timeframe: from [start of treatment] through 28 days after
Serum urea change over time
Timeframe: from [start of treatment] through 28 days after
Urine output change
Timeframe: from [start of treatment] through 28 days after